An end-to-end population genomics platform

From recruitment support to Exome+® sequencing to return of results, we enable you to bring the power of genomics to your communities.

DNA Helix in shades of blue

A panel-grade clinical exome

The Exome+ assay delivers the benefits of a targeted panel, the breadth of a microarray, and the completeness of an exome all from one assay

Beaker in shades of blue

Genomics research platform

The Helix platform, with its dedicated clinical and research teams, supports you in delivering actionable genetic insights and conducting large-scale genetic analyses

Lightbulb in shades of blue

Sequence once, query often

Helix sequences and securely stores Exome+ data on behalf of each participant enabling flexible and on-demand access to genomic data, with the proper consent

COVID-19 testing

We've launched a sensitive, scalable, end-to-end COVID-19 test system to meet the needs of health systems, employers, governments, and other organizations across the country.


Our test system includes a non-invasive collection kit, processing of samples in our CLIA-certified, CAP-accredited high-complexity laboratory in San Diego, next-day turnaround time, and return of results to the ordering healthcare professional, the tested individual, and public health agencies, as necessary.

Learn more

NIH RADx award for COVID-19 testing

Helix has been awarded $33.4 M in funding from the National Institutes of Health (NIH) under the Rapid Acceleration of Diagnostics (RADx) program. These funds will support rapid scaling of our COVID-19 infrastructure and operations, with a goal of reaching a capacity of 100,000 COVID-19 tests per day.

Learn more


Privacy is one of our top priorities.

We won’t share data without a participant’s permission. We pledge to uphold the highest standards of bioethics and maintain rigorous policies and procedures to keep data safe and secure.

Learn how we protect data

Partner with us

Helix provides the infrastructure and services to help you carry out population-scale genomic screening and research initiatives, including one of the world's largest CLIA / CAP next-generation sequencing labs. Together, we can drive earlier identification of at-risk individuals and accelerate innovative research efforts.

Learn more

*Panel-grade: defined as a ~100% call rate across every base within clinically relevant panels (offering equivalent or superior quality to clinical panels in the market).